APA 6th Edition

Grabljevec, K. (2022). OUTCOMES IN REHABILITATION FOLLOWING PATIENT SELECTION FOR THE MANAGEMENT OF DISABLING SPASTICITY WITH INTRATHECAL BACLOFEN AND/OR BOTULINUM TOXIN TYPE A. Fizikalna i rehabilitacijska medicina, 36 (1-2), 20-22. https://doi.org/10.21751/FRM-36-1-2-9

---

MLA 8th Edition

Grabljevec, Klemen. "OUTCOMES IN REHABILITATION FOLLOWING PATIENT SELECTION FOR THE MANAGEMENT OF DISABLING SPASTICITY WITH INTRATHECAL BACLOFEN AND/OR BOTULINUM TOXIN TYPE A." Fizikalna i rehabilitacijska medicina, vol. 36, no. 1-2, 2022, pp. 20-22. https://doi.org/10.21751/FRM-36-1-2-9. Accessed 19 Dec. 2024.

---

Chicago 17th Edition

Grabljevec, Klemen. "OUTCOMES IN REHABILITATION FOLLOWING PATIENT SELECTION FOR THE MANAGEMENT OF DISABLING SPASTICITY WITH INTRATHECAL BACLOFEN AND/OR BOTULINUM TOXIN TYPE A." Fizikalna i rehabilitacijska medicina 36, no. 1-2 (2022): 20-22. https://doi.org/10.21751/FRM-36-1-2-9

---

Harvard

Grabljevec, K. (2022). 'OUTCOMES IN REHABILITATION FOLLOWING PATIENT SELECTION FOR THE MANAGEMENT OF DISABLING SPASTICITY WITH INTRATHECAL BACLOFEN AND/OR BOTULINUM TOXIN TYPE A', Fizikalna i rehabilitacijska medicina, 36(1-2), pp. 20-22. https://doi.org/10.21751/FRM-36-1-2-9

---

Vancouver

Grabljevec K. OUTCOMES IN REHABILITATION FOLLOWING PATIENT SELECTION FOR THE MANAGEMENT OF DISABLING SPASTICITY WITH INTRATHECAL BACLOFEN AND/OR BOTULINUM TOXIN TYPE A. Fizikalna i rehabilitacijska medicina [Internet]. 2022 [cited 2024 December 19];36(1-2):20-22. https://doi.org/10.21751/FRM-36-1-2-9

---

IEEE

K. Grabljevec, "OUTCOMES IN REHABILITATION FOLLOWING PATIENT SELECTION FOR THE MANAGEMENT OF DISABLING SPASTICITY WITH INTRATHECAL BACLOFEN AND/OR BOTULINUM TOXIN TYPE A", Fizikalna i rehabilitacijska medicina, vol.36, no. 1-2, pp. 20-22, 2022. [Online]. https://doi.org/10.21751/FRM-36-1-2-9